Skip to main content
Log in

Cost effectiveness of PCV13 vaccination in doubt when including future costs and benefits

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • de Vries LM, et al. Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. Vaccine : 8 Jun 2021. Available from: URL: http://doi.org/10.1016/j.vaccine.2021.05.091

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost effectiveness of PCV13 vaccination in doubt when including future costs and benefits. PharmacoEcon Outcomes News 881, 5 (2021). https://doi.org/10.1007/s40274-021-7801-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7801-1

Navigation